Advertisement
Singapore markets closed
  • Straits Times Index

    3,304.00
    +2.22 (+0.07%)
     
  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     
  • Dow

    38,834.86
    +56.76 (+0.15%)
     
  • Nasdaq

    17,862.23
    +5.21 (+0.03%)
     
  • Bitcoin USD

    65,339.48
    -114.79 (-0.18%)
     
  • CMC Crypto 200

    1,385.76
    +48.01 (+3.59%)
     
  • FTSE 100

    8,195.80
    +4.51 (+0.06%)
     
  • Gold

    2,343.30
    -3.60 (-0.15%)
     
  • Crude Oil

    81.37
    -0.20 (-0.25%)
     
  • 10-Yr Bond

    4.2170
    -0.0620 (-1.45%)
     
  • Nikkei

    38,570.76
    +88.65 (+0.23%)
     
  • Hang Seng

    18,430.39
    +514.84 (+2.87%)
     
  • FTSE Bursa Malaysia

    1,599.79
    -6.34 (-0.39%)
     
  • Jakarta Composite Index

    6,726.92
    -7.91 (-0.12%)
     
  • PSE Index

    6,366.03
    -2.77 (-0.04%)
     

Here's How Moderna Plans to Win in the Post-Emergency COVID Vaccine Market

Here's How Moderna Plans to Win in the Post-Emergency COVID Vaccine Market

High demand for coronavirus vaccines earlier in the pandemic pushed Moderna's (NASDAQ: MRNA) earnings into the stratosphere. In fact, Moderna could continue to generate billions in revenues annually from its first -- and so far, only -- approved product. For example, Moderna sold its vaccine to the U.S. government for about $26 a dose.